<PAGE>
EXHIBIT 10.93
* CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY THE
BRACKETS, HAS BEEN OMITTED AND FILED WITH
THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24b-2 OF THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED.
AMENDMENT NO. 4 TO ENBREL SUPPLY AGREEMENT
THIS AMENDMENT NO. 4 TO ENBREL SUPPLY AGREEMENT (this "Amendment")
is
effective as of October 31, 2003 between
and among Genentech Inc., a Delaware
corporation ("Genentech"), and Immunex
Corporation, a Washington corporation and
a wholly owned subsidiary of Amgen Inc.
("Immunex") (collectively the
"Parties").
Genentech and Immunex are parties to that certain Enbrel Supply
Agreement dated April 12, 2002, as amended
by that certain Amendment No. 1 to
Enbrel Supply Agreement dated September 20,
2002, that certain Amendment No. 2
dated July 16, 2002 and that certain
Amendment No. 3 to Enbrel Supply Agreement
dated March 26, 2003 (as amended, the
"Agreement").
WHEREAS Genentech had initially provided Immunex with a forecast
which
provided that [*];
WHEREAS Immunex requested that [*];
WHEREAS Genentech has agreed to [*];
WHEREAS in order to accommodate Immunex's request for [*],
Genentech
has had to [*];
WHEREAS the Parties are agreeable to [*];
WHEREAS the Parties are agreeable to [*].
NOW, THEREFORE, for good and valuable consideration, the receipt
and
sufficiency of
